FDA Approves NUMELVI for Dogs from Merck Animal Health - The First and Only Second-Generation Janus Kinase Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis
Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir , an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026
Merck Announces Positive New Data for ENFLONSIA for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus Disease Over Two RSV Seasons
Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine
Health Canada Approves KEYTRUDA SC, a subcutaneous formulation of pembrolizumab across multiple cancer indications
Health Canada Approves KEYTRUDA SC, a subcutaneous formulation of pembrolizumab across multiple cancer indications
Health Canada Approves KEYTRUDA SC, a subcutaneous formulation of pembrolizumab across multiple cancer indications
Merck Announces Health Canada Approval of ENFLONSIA® for the prevention of RSV in newborns and infants
Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline
Domestic Metals Completes Surface IP Geophysical Survey at Smart Creek and Announces Amendment to Warrant Terms of Unit Private Placement
RETRANSMISSION: West High Yield Resources Ltd. Signs Definitive Forward Sales Agreement to Sell Magnesium Ore from Its Record Ridge Project
Anteros Metals Reports Assay Results from RM26-01 and Provides Exploration Update at the Seagull Critical Minerals Project, Ontario
